SDF-1 Antibody [M4G11] Datasheet

Biological Description

Specificity	SDF-1 Antibody [M4G11] detects endogenous levels of total SDF-1 protein.
Background	SDF‑1, also known as CXCL12, is a CXC chemokine that serves as a key retention and homing signal for CXCR4‑expressing hematopoietic and endothelial progenitor cells, neural cells, and various leukocyte subsets, positioning it as a central organizer of tissue colonization, immune cell trafficking, and repair responses in multiple organs including bone marrow, ischemic tissues, and the nervous system. The chemokine adopts the typical chemokine fold with an N‑terminal region required for receptor activation, a three‑stranded β‑sheet, and a C‑terminal α‑helix that participates in receptor and glycosaminoglycan binding, forming gradients on stromal and endothelial surfaces that direct CXCR4‑positive cells along SDF‑1 concentration fields. Binding of SDF‑1 to the G protein–coupled receptor CXCR4 triggers Gi‑dependent signaling and rapid phosphorylation of focal adhesion–associated proteins such as RAFTK/Pyk2, FAK, paxillin, p130Cas, and Crk family adaptors, which reorganizes focal adhesions and the actin cytoskeleton and drives directional migration of CD34‑positive hematopoietic progenitor cells toward SDF‑1 sources. CXCR4 engagement also recruits and activates PI3K and protein kinase C, and inhibition of these enzymes blocks SDF‑1–induced phosphorylation of focal adhesion proteins and migratory responses, placing PI3K and PKC as essential intermediates that connect chemokine receptor activation to adhesion dynamics and motility, while ERK1/2 activity is dispensable for this specific migratory program. In bone marrow niches, sustained SDF‑1 production by stromal and endothelial cells retains CXCR4‑positive hematopoietic and pro‑angiogenic cells, whereas modulation of the SDF‑1 gradient or CXCR4 activity mobilizes these cells into the circulation, linking this axis directly to stem and progenitor cell trafficking during homeostasis, ischemic repair, and tumor angiogenesis. Within ischemic and tumor environments, elevated SDF‑1 levels recruit CXCR4‑positive VEGFR1‑positive hematopoietic cells and endothelial progenitors to sites of neovascularization, and engagement of CXCR4 on vascular cells and stromal elements enhances revascularization, vessel stabilization, and support of tissue remodeling or tumor growth. In the nervous system, SDF‑1, acting through CXCR4 on neural progenitors, cerebellar granule cells, microglia, astrocytes, and nociceptive neurons, regulates migration, proliferation, cytokine and glutamate release, synaptic responses, and nociceptive signaling, thereby contributing to brain development, neuroinflammatory modulation, and pain pathways. The chemokine–receptor pair participates in pathophysiological processes that include brain tumors, experimental allergic encephalitis, and HIV‑associated nervous system dysfunction, where altered SDF‑1/CXCR4 signaling affects leukocyte infiltration, glial activation, and neuronal survival or excitability. In ischemic cardiovascular disease and cancer, SDF‑1/CXCR4 acts as a molecular hub for neo‑angiogenesis by coordinating recruitment and retention of pro‑angiogenic bone marrow cells and by directly influencing endothelial and stromal cells, and pharmacologic modulation of this axis, such as CXCR4 antagonism, alters the balance between progenitor mobilization and sustained recruitment to angiogenic niches.

Specificity

SDF-1 Antibody [M4G11] detects endogenous levels of total SDF-1 protein.

Background

SDF‑1, also known as CXCL12, is a CXC chemokine that serves as a key retention and homing signal for CXCR4‑expressing hematopoietic and endothelial progenitor cells, neural cells, and various leukocyte subsets, positioning it as a central organizer of tissue colonization, immune cell trafficking, and repair responses in multiple organs including bone marrow, ischemic tissues, and the nervous system. The chemokine adopts the typical chemokine fold with an N‑terminal region required for receptor activation, a three‑stranded β‑sheet, and a C‑terminal α‑helix that participates in receptor and glycosaminoglycan binding, forming gradients on stromal and endothelial surfaces that direct CXCR4‑positive cells along SDF‑1 concentration fields. Binding of SDF‑1 to the G protein–coupled receptor CXCR4 triggers Gi‑dependent signaling and rapid phosphorylation of focal adhesion–associated proteins such as RAFTK/Pyk2, FAK, paxillin, p130Cas, and Crk family adaptors, which reorganizes focal adhesions and the actin cytoskeleton and drives directional migration of CD34‑positive hematopoietic progenitor cells toward SDF‑1 sources. CXCR4 engagement also recruits and activates PI3K and protein kinase C, and inhibition of these enzymes blocks SDF‑1–induced phosphorylation of focal adhesion proteins and migratory responses, placing PI3K and PKC as essential intermediates that connect chemokine receptor activation to adhesion dynamics and motility, while ERK1/2 activity is dispensable for this specific migratory program. In bone marrow niches, sustained SDF‑1 production by stromal and endothelial cells retains CXCR4‑positive hematopoietic and pro‑angiogenic cells, whereas modulation of the SDF‑1 gradient or CXCR4 activity mobilizes these cells into the circulation, linking this axis directly to stem and progenitor cell trafficking during homeostasis, ischemic repair, and tumor angiogenesis. Within ischemic and tumor environments, elevated SDF‑1 levels recruit CXCR4‑positive VEGFR1‑positive hematopoietic cells and endothelial progenitors to sites of neovascularization, and engagement of CXCR4 on vascular cells and stromal elements enhances revascularization, vessel stabilization, and support of tissue remodeling or tumor growth. In the nervous system, SDF‑1, acting through CXCR4 on neural progenitors, cerebellar granule cells, microglia, astrocytes, and nociceptive neurons, regulates migration, proliferation, cytokine and glutamate release, synaptic responses, and nociceptive signaling, thereby contributing to brain development, neuroinflammatory modulation, and pain pathways. The chemokine–receptor pair participates in pathophysiological processes that include brain tumors, experimental allergic encephalitis, and HIV‑associated nervous system dysfunction, where altered SDF‑1/CXCR4 signaling affects leukocyte infiltration, glial activation, and neuronal survival or excitability. In ischemic cardiovascular disease and cancer, SDF‑1/CXCR4 acts as a molecular hub for neo‑angiogenesis by coordinating recruitment and retention of pro‑angiogenic bone marrow cells and by directly influencing endothelial and stromal cells, and pharmacologic modulation of this axis, such as CXCR4 antagonism, alters the balance between progenitor mobilization and sustained recruitment to angiogenic niches.

Usage Information

Application

WB, IHC, IF

Dilution

WB	IF	FCM
1:10000-1:50000	1:100-1:250	1:20

Reactivity

Human

Source

Rabbit Monoclonal Antibody

MW

11 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/12655598/
https://pubmed.ncbi.nlm.nih.gov/17560169/

SDF-1 Antibody [M4G11]

Biological Description

Usage Information

References

Application Data